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Ellagic acid (EA) is a polyphenolic active compound with antimalarial and other promising 
therapeutic activities. However, its solubility and its permeability are both low (BCS IV). These 
properties greatly compromise its oral bioavailability and clinical utilizations. To overcome 
these limitations of the physicochemical parameters, several formulation approaches, including 
particle size reduction, amorphization and lipid-based formulations, have been used. Although 
these strategies have not yet led to a clinical application, some of them have resulted in 
significant improvements in the solubility and bioavailability of EA. This critical review reports 
and analyses the different formulation approaches used by scientists to improve both the 
biopharmaceutical properties and the clinical use of EA.   
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Over the last twenty years, the increasing number of active pharmaceutical ingredients (APIs) 
with low solubility has become one of the major challenges in pharmaceutical research [1]. 
Indeed, an important fraction of the new drug candidates emerging from drug discovery 
programs have poor water solubility. It is estimated that 75% of drug candidates and 
approximately 40% of currently marketed drugs are poorly water soluble [2,3]. This 
unsatisfactory physicochemical property of APIs leads to poor absorption and poor 
bioavailability and the need for high drug dosage to be administered, leading to increased side 
effects [4]. The other important factor to consider in drug development is the ability of a drug 
molecule to cross a mucosal barrier into the systemic circulation. An interesting example of 
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API with major biopharmaceutical challenges is ellagic acid (EA). Discovered by Henri 
Braconnot in 1831, EA is a polyphenolic active compound with high nutritional and therapeutic 
beneficial effects for human health [5,6]. It is widely distributed in many tropical and 
mediterranean plant species such as Adenium obesum (Apocynaceae), Terminalia chebula 
(Combretaceae), Rosa rugosa (Rosaceae) and Punica granatum (Lythraceae) [7–9] . In plants, 
EA is found in free form or linked to sugars or polyols, forming ellagitannins or hydrolysable 
tannins [10].
Today, a considerable number of non-drugs such as botanicals and enriched foods containing 
ellagitannins and/or EA, are commercially available as nutraceuticals and used to prevent many 
oxidative-linked chronic diseases, including cancer, diabetes, cardiovascular and 
neurodegenerative diseases [11,12]. This use of both EA and ellagitannins led to a shortage of 
pomegranate juice, a rich food source of EA and ellagitannins, in american supermarkets in 
2007 [13,14]. Indeed, pomegranate juice contains between 2020 and 2660 mg of mixture of EA 
and ellagitannins per liter. Very high mean concentrations of EA have been also detected in 
different varieties of raspberry (Rubus idaeus L., Rosaceae) (190-719 mg/100 g), in cloudberry 
(Rubus chamaemorus L., Rosaceae) (644 mg/100 g) and artic bramble (Rubus arcticus, 
Rosaceae) (390 mg/ 100 g). The daily intake of EA through the consumption of foods, remains 
difficult to assess because of the limited knowledge about the EA foods content. However it is 
estimated to be between 0.2 and 0.3 mg in France, 5 mg in Germany, 12 mg in Finland and 
between 11.8 and 55 mg in the USA [14–16].
In addition to these nutritional supplement properties, various studies have confirmed that EA 
has antimalarial, anti-nociceptive, anti-proliferative, anti-mutagenic, hepatoprotective, anti-
diabetic and cardioprotective activities and is useful in the treatment of neurodegenerative 
diseases [6,17–19]. This multifaceted health activity of EA could be mainly ascribed to its 
antioxidant property and free radical trapping ability, that results in preventing or reducing the 
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so called “Oxidative Stress” [20]. If the daily intake of EA from food is useful for the prevention 
of some diseases, its therapeutic utilization, as for example in the treatment of malaria by oral 
route, remains a great challenge because of its low oral overall bioavailability, with typical 
plasma concentrations of 0.1–0.4 µmol / L [21,22]. This  low bioavailability is mainly due to 
its low aqueous solubility associated with low membrane permeability, a significant first pass 
effect and irreversible binding to cellular DNA and proteins [23].
In order to allow an effective therapeutic application of EA, it is therefore necessary to develop 
strategies that sufficiently enhance its solubility, stability and bioavailability. Thus, during the 
last twenty years, researchers investigated the enhancement of solubility and bioavailability of 
this API through different approaches. This review proposes to analyze the physical formulation 
approaches studied by these scientists to try to overcome the biopharmaceutical challenges of 
EA.
2. Structure and properties of ellagic acid
Also known as a gallic acid dimer, EA or 2,3,7,8-tetrahydroxy [1] -benzopyranol [5,4,3-cde] 
benzopyran-5,10-dione is, from the physicochemical point of view, in the form of an ocher-
yellow crystalline powder with a melting point above 360°C, a boiling point of 796.5°C, a log 
P of 1.05, a molecular weight of 302.197 g mol-1 [23]. Its chemical structure (fig. 1) includes 
four hydroxyl groups and two lactone groups representing the hydrophilic moiety and a 
lipophilic planar moiety consisting of two hydrocarbon phenyl rings. Hydroxyl groups and the 
lactone systems can act as electron acceptors and they can interact to form hydrogen bonds. EA 
is thus endowed with the ability to accept electrons from different substrates as well as to 
participate in antioxidant redox reactions [24,25]. The molecular mechanisms activated by EA 
are multiple. They include free radical scavenging, regulation of phase I and II enzymes, 
modulation of pro-inflammatory and profibrotic cytokine synthesis, regulation of biochemical 
pathways involved in lipid synthesis and degradation, and maintenance of essential trace 
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element levels. Moreover, EA inhibits hepatic stellate cells and mast cells activation, the 
proliferation of transformed cells, as well as viral replication by increasing antioxidant 
response, induction of apoptosis, downregulation of genes involved in cell cycle and 
angiogenesis, and stimulation of cellular immune response [26,27].
Fig. 1: Chemical structure (A) and three-dimensional molecular size (B) of EA. Adapted with 
permission from [28].
This polyphenolic active compound possesses a high degree of crystallinity resulting from both 
its planar and symmetrical structure and an extensive network of hydrogen bonds involving 
trivial water solubility. Indeed, EA is practically insoluble in water (less than 10 µg/mL) [29] 
but soluble in methanol, N-methyl pyrrolidone, pyridine, polyethylene glycol (PEG) 400, 
dimethyl sulfoxide and triethanolamine. PEG 400 is the best solvent, reaching concentrations 
of up to 8 mg mL-1. As a weak acid, its solubility increases with pH and is higher in phosphate 
buffer at pH 7.4 (33.1 µg/ml) [30]. With this low aqueous solubility, EA is thus a dissolution-
limited resorption substance [31]. Table 1 summarizes the physicochemical characteristics of 
EA.
Table I : Physicochemical properties of ellagic acid 
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Property name Property Value Reference
Molecular Weight 302.19 gmol-1
Aqueous solubility 9.73 µg/ml 
[6]
Melting Point Greater than 360°C [32]
Log P 1.05 [23]
Hydrogen Bond Donor Count 4
Hydrogen Bond Acceptor Count 8
PubChem CID: 
5281855)
Dissociation Constants pKa1 = 6.69
pKa2 = 7.45
 pKa3 = 9.61
pKa4 = 11.50
[33]
Spectral Properties UV max  UV max (ethanol): 366, 255 nm [5]
Decomposition temperature 631° C [34] 
A pharmacokinetic study of EA in healthy volunteers, showed that a higher free EA intake did 
not enhance its bioavailability but promotes urolithin production. Interestingly, this study has 
identified three representative pharmacokinetic profiles, i.e. a bell-shaped profile with Tmax 
around 1.5–2 h, a profile with two Tmax, and a profile where Tmax was detected after 24 h of 
EA and punicalagin (the ellagitannin form found in pomegranate) intake. Furthermore, a large 
inter-individual variability in terms of the amount of EA absorbed was also observed. This 
behavior is inherent to the limited EA bioavailability and could be mainly related to its low and 
pH-dependent solubility [35]. In addition to this low aqueous solubility, the membrane 
permeability of the EA is around 1.3 × 10−7 cm s−1 in human intestinal caco-2 cells, well below 
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the classifying threshold value of  2 × 10−4 cm s−1 [36]. Indeed, if the effective permeability of 
a drug is higher than 2 × 10−4 cm s−1, then complete drug absorption will be considered, 
otherwise, drug permeability is low and the absorption is incomplete [37]. The absorption sites 
of free EA into circulation are either the stomach or small intestine [10,15]. Ellagitannins 
resistant to acid hydrolysis, as well as degradation in the stomach, release EA in the small 
intestine at a neutral to slightly basic pH, which in turn may allow some freed EA to be absorbed 
in the small intestine [38]. The unabsorbed EA and ellagitannins suffer extensive metabolism 
by the gut microbiota to produce urolithins that are much better absorbed [39]. The health 
effects attributed to urolithins are close to those of the EA. Recent research, mostly based on in 
vitro testing, has shown preliminary evidence of the anti-inflammatory, anticarcinogenic, 
antiglycative, antioxidant, and antimicrobial effects of urolithins [39,40]. The absorbed EA is 
rapidly eliminated from the systemic circulation suggesting an efficient first-pass metabolism. 
During first-pass metabolism, EA is converted to methyl esters, dimethyl esters, and 
glucuronides. These metabolites and urolithins  are eliminated in the urine [41]. However, the 
data from these pharmacokinetic studies are controversial and need further investigations.
With regard to these solubility and intestinal epithelium permeability data, EA therefore 
belongs into class IV of the biopharmaceutical classification system (BCS). The BCS classifies 
drugs into four classes in order to find the best solutions to oral bioavailability concerns [42]. 
Thus, drugs with both high permeability and high solubility are in class 1; drugs with high 
permeability but low solubility are in class 2; drugs with low permeability but high solubility 
are in class 3; and finally, class 4 includes drugs with both low solubility and low permeability 
[43,44].
Approaches used to remedy unsatisfactory biopharmaceutical properties of APIs like EA are 
commonly based on chemical or physical modifications. Chemical modifications include the 
development of prodrugs, salt formation and co-crystal design [45]. These modifications are 
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limited to select drugs and are a lengthy and costly process. For instance, a limited number of 
APIs have desired functional groups such as ionizable or polar groups with potential for salt 
formation [46]. In addition, changing one property can adversely affect the others. This is 
observed when structural modifications that enhance solubility of APIs often also increase the 
toxicity and decrease permeability. Compared to chemical modifications, the physical 
formulation approaches are applicable to a wider group of APIs, are easier to prepare, and are 
usually preferred by industries [47]. They involve particle size reduction, modification of the 
crystalline form, liquid formulation and complexation with cyclodextrins [48,49]. Fig. 2 
provides an overview of the most important formulation approaches to enhance the aqueous 
solubility and bioavailability of poor water-soluble drugs.
The specific formulation approaches and methods used by authors to enhance the aqueous 
solubility and biopharmaceutic profile of EA are extensively described below. 
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Fig. 2: Overview of the most important formulation approaches to improve the solubility of 
drugs. Adapted with permission from [31].
3. Formulation approaches to improve solubility and bioavailability of ellagic acid
3.1 Amorphization
The amorphous form of API is used to improve their solubility and dissolution rate [50]. Indeed, 
due to the improvement of thermodynamic properties and the absence of crystalline lattice to 
break (fig.3), the amorphous form has a greater solubility (1.1 to 1000 fold) than that of the 
crystalline one [45]. The amorphous form can be obtained through various ways, but the most 
common of them are fast cooling and precipitation from solutions [51]. However, the 
amorphous form is very unstable and tends to recrystallize [52,53]. To overcome this instability, 
the formation of amorphous solid dispersions (ASD), the use of mesoporous systems and the 
co-amorphization are often carried out. The polymer-based solid dispersion formation is one of 
the most promising techniques because of its universal potential to improve the bioavailability 
of any API. This technique is based on the use of several methods of which the main ones are 
melt-based methods like hot melt extrusion and those based on solvent evaporation such as 
spray drying, coprecipitation or rotary evaporation [54,55].
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Fig. 3: Activation energy diagram for the solubilization of a drug from a crystalline form (left) 
and from an ASD (right). Ea is the energy required to disrupt crystalline lattice of a drug in a 
conventional formulation; Ec is the energy required to disrupt the glass solution of a drug in an 
ASD formulation, Eb is the energy required for solvent cavitation in the solubilization of a 
crystalline solid and Ed is the energy required for solvent cavitation in the case of ASD 
solubilization. Reprint with permission from [56].
By using the solvent-evaporation methods, Li et al. (2013) evaluated the ability of cellulose 
derivatives such as carboxymethylcellulose acetate butyrate (CMCAB), cellulose adipate 
propionate (CAAdP) and hydroxypropyl methylcellulose acetate succinate (HPMCAS) to form 
ASD with EA, in order to improve its solubility. The release profiles of these resulting solid 
dispersions (SD) were carried out by dissolution tests and were compared to those of pure EA 
and SD of EA in polyvinyl pyrrolidinone (PVP), a widely and historically known ASD polymer. 
They observed that the release of EA from PVP SD was more rapid and complete (≈100%) at 
pH 6.8, followed by those from HPMCAS and CMCAB (fig.4 B). At pH 1.2. However, EA 
was also released from PVP (≈ 40%) and then recrystallizes rapidly (fig.4 A), arising the 
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problem of rational choice of nature and quantity of polymer used for API stabilization in ASD. 
Indeed, a good affinity and a reasonable proportions of API and polymer are necessary to slow 
down the recrystallization of the dissolved molecule [57]. The X-ray diffraction and Fourier 
transform infrared spectroscopy (FTIR) results indicated that EA was amorphous in HPMCAS 
and PVP SD at the EA proportion up to 25 wt%, and in CMCAB and CAAdP SDs at the EA 
concentration up to 10 wt% [32]. The maximum EA concentration from amorphous dispersion 
obtained by dissolution test at pH 6.8 was 1500 µg/mL with PVP and 280 µg/mL with 
HPMCAS corresponding to increases of more than 45 and 8 times the actual EA solubility.
Fig. 4 : Release profiles of an equivalent of 5 mg of EA from solid dispersions (SD) produced 
by solvent evaporation methods as a function of time. EA/CMCAB 1/9 SD, EA/HPMCAS 1/9 
SD and EA/PVP 1/9 SD correspond to EA/polymer solid dispersions in a ratio of 1/9 w/w. 
EA/PVP 1/9 PM is the physical mixture in the same ratio. These dissolution tests were carried 
out at pH 1.2 (A) and pH 6.8 (B). Reprint with permission from [32]. 
The high crystal lattice force of EA (melting point ˃  360°C) is at the origin of its poor solubility. 
Therefore, the realization of ASD is one of the best ways to circumvent the problem of poor 
aqueous solubility [58]. Indeed, the solubility of the drug substance in the ASD is improved by 
disrupting its crystalline lattice to produce a higher energy amorphous form [59,60]. This 
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concept was proved by Li et al. showing the increase of solubility from the ASD. However, 
Figure 4 shows a decrease in the EA concentration from the maximum values, presumably due 
to incomplete stabilization of supersaturated EA concentrations by the polymers. Indeed, a 
rational choice of the polymer could allow it to inhibit the crystallization of the amorphous EA 
from the solid carrier matrix and the supersaturated solution that is created upon dissolution. 
Authors chose cellulose derivatives for their study mainly because they are effective ASD 
polymers and PVP because it is a widely and historically known ASD polymer. Their choice 
was not based on possible strong attractive EA-polymer interactions, which could explain the 
instability of the supersaturated EA solution. Instability is the major drawback of amorphous 
forms, if not controlled, it can lose the advantage of these forms in terms of improved solubility 
compared to crystalline forms [61].
3.2 Complexation with cyclodextrins
Cyclodextrins (CD) are cyclic oligosaccharides formed from α-D-glucopyranose units, linked 
by α- (1-4) glycosidic bonds [62]. Natural cyclodextrins differ according to the number of α-D-
glucopyranose units which can range from six to twelve [63], the most common being α, β, γ-
cyclodextrin with 6, 7 and 8 α-D-glucopyranose units, respectively. The volume and diameter 
of the internal cavity of native cyclodextrins (Fig.5), which are 174 Ä 3 and 5.7Ä, 262 Ä 3 and 
7.8 Ä and 427 Ä3 and 9.5 Ä, respectively for the αCD, βCD and γCD, increases with the number 
of glucopyranose units. The aqueous solubility does not follow this logic since at 25 ° C, it is 
145 mg/mL, 18.5 mg/mL and 232 mg/mL for αCD, β-CD and γCD [64,65].
Cyclodextrins have a relatively hydrophobic central cavity furnished with carbon and hydrogen 
atoms and a relatively hydrophilic exterior furnished with primary hydroxyl groups (attached 
to C6 carbons) and secondary (attached to C2 carbons and C3). This configuration allows them 
to form inclusion complexes with a wide range of solid, liquid or gaseous substances [66]. In 
1953, Freudenberg et al. demonstrated that inclusion complexes in CDs increase the solubility 
15
of poorly soluble drugs, reduce the loss of volatile substances and protect oxidizable substances 
from oxidation [67]. Brewster and Loftsson (2007) estimated that inclusion complexes increase 
the bioavailability of poorly soluble drugs by 1.1 to 49 times, compared to that of crystalline 
and lyophilized drugs used as control formulations [68]. Thus, the use of CDs by the 
pharmaceutical industry nowadays is estimated at more than 3000 tons per year, i.e. 30% of 
annual production [69]. CDs and their derivatives, mainly the methylated, hydroxypropyl and 
sulfobutyl ethers, are currently found in over 50 marketed pharmaceutical products. They are 
used as excipient to protect APIs from specific and non-specific interactions in physiological 
media [70], to improve the permeability of drugs by interacting and destabilizing biological 
membranes [71], to modulate the rate and site of drug release [72] and finally, to increase their 
aqueous solubility [73–75].
The different methods developed to prepare inclusion compounds are liquid phase method, co-
precipitation, kneading or slurry method, extrusion, damp mixing, dry mixture and co-grinding, 
spray drying and lyophilization [63].
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Fig. 5 : Modelisation of the structures of the three main natural cyclodextrins (A), diagram of 
a α-D-glucopyranose unit (B), and annotated diagram of a cyclodextrin (C). Adapted with 
permission from [76].
In order to evaluate the antimicrobial and antioxidant activity of EA, Savic et al. prepared 
inclusion complexes, using β-CD and hydroxypropyl β-CD (HP β-CD). The inclusion 
complexes were prepared by suspending EA and CDs in distilled water. The suspensions were 
stirred on a magnetic stirrer at 600 rpm and room temperature for 24 h, then evaporated on a 
rotary vacuum evaporator at 60°C and dried in a desiccator until a constant mass. The obtained 
complexes were further characterized by FTIR, XRD and nuclear magnetic resonance methods. 
The aqueous phase solubility study carried out by adding an excess of EA to 5 mL CD solutions 
(0-10 mM), showed that the EA solubility in 10 mM solutions of β-CD and HP- β-CD was 
respectively 2.2 and 2.6 times higher, than that observed in water without CDs. An AL-type 
diagram (fig.6) was obtained with both CDs and the stability constants were 161 dm3 mol-1 and 
117 dm3 mol-1 for the complex with HP- β-CD and β-CD respectively [77].
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Fig. 6 : Diagram of the phase solubility of EA in the presence of increasing concentrations of 
β-CD and HP-β-CD (0 -10 mM) in water at 25° C for a 24 h equilibration time. Reprint with 
permission from [77].
 Other authors prepared complexes of EA and HPβ-CD by freeze-drying and studied the 
mechanism of complexation, using different analytical techniques including FTIR, powder X-
ray diffraction, nuclear magnetic resonance, scanning electron microscopy and molecular 
modeling. The phase solubility study carried out with concentrations ranging from 0 to 24 mM 
of HPβ-CD in the presence of an excess of EA showed an AN type diagram, according to the 
classification of Higuchi and Connors (fig.7 A). In addition, the results of the dissolution tests 
carried out with pure EA, physical mixture (PM) and inclusion complex (EA - HPβ-CD) 
showed that the inclusion complex EA/HP-β-CD released up to 55% and 60 % of the drug into 
15 and 30 min respectively, whereas pure EA showed a release of 10% after 15 min and up to 
13% after 60 min (fig.7 C) [78]. Moreover, inclusion complexes of EA with β-CD prepared by 
freeze-drying significantly enhanced the aqueous solubility of EA (fig. 7 B) since it passed from 
10.37 µg/ml to 39.14 µg/ml, which corresponds to an increase of 3.77 times of the intrinsic 
solubility. The results of the dissolution tests (fig.7 D) also showed a release rate of 27% in 30 
min with the complex while that of pure EA only reached 13% after 60 min [79].
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Fig. 7 : Diagram of the phase-solubility of EA with increasing concentrations (0-24 mM) of 
HP-β-CD (A) and β-CD (B) in water at 30° C for a 72 h equilibration time. Dissolution rate 
profiles of pure EA (EA), physical mixture (PM) and EA-CD inclusion complex of EA-HP- β-
CD inclusion complex (C) and EA-β-CD inclusion complex (D). These assays have been 
performed with equivalent amounts of 100 mg of EA. Reprint with permission from [67] for 
picture A and C, and [68] for picture B and D.
Chudasama et al. evaluated the bioavailability of EA complexed with methyl β-cyclodextrin 
(Me-β-CD) in rats. Thirty minutes after administration by gavage of a single dose of either EA 
(0.4 g/kg in 0.5% carboxymethylcellulose) or EA complexed with Me-β-CD (1:2 molar ratio), 
plasma levels of EA were 7-fold higher in EA/Me-β-CD treated rats than in EA treated rats, i.e. 
36.61 + 14.12 ng/ml and 5.63 + 9.8 ng/ml, respectively. However, the authors did not specify 
the nature of the Me-β-CD used or the method of complexation [80]. Mady et al. (2018) 
estimated the effect of EA / β-CD inclusion complexes on solubility and bioavailability of EA. 
19
The team found solubility of 49.79 µg/ml and 9.73 µg/ml, respectively for the inclusion 
complexes and pure EA. The bioavailability in animals was 1345.49 ng.hr.ml-1 for the inclusion 
complex versus 598.94 ng.hr.ml-1 for pure EA [81].
To perform inclusion, the substrate size has to be inferior to that of the cyclodextrin interior 
cavity and the driving energy for the various actors of inclusion, namely the cyclodextrin, the 
API and the solvent have to be favorable. Indeed, water molecules located in the cyclodextrin 
cavity have to be more easily replaced by less polar molecules [77]. Despite the size of the EA 
molecule (fig. 1), its low lipophilicity (log P=1.05), its planar structure which may limit its 
inclusion in the CD cavity due to steric effects, β-CD and derivatives have been successfully 
used as EA solubilizers.  This could be explained by the formation of partial inclusion 
complexes involving carboxyl groups of EA and by the formation of association complexes 
involving hydroxyl groups. Based on the results of phase solubility studies, a linear increase of 
the EA solubility is observed in presence of increasing concentrations of β-CD and HP-β-CD 
up to 12 mM. Beyond that, the relationship is no longer linear. However, compared to the ASD 
formation approach, EA complexing with cyclodextrins seems to be less successful in terms of 
solubility improvement. In addition, developing a cyclodextrin-based drug is relatively 
expensive and is often limited to powerful drugs that can be used at low doses [31]. 
3.3 Particle size reduction
Reducing the particle size is one of the most interesting approaches to improve the 
bioavailability of substances poorly soluble in water. Indeed, it significantly increases the 
specific surface which, according to the modified Noyes and Whitney equation, increases the 
dissolution rate and consequently the bioavailability [82]. In addition, this approach also 
increases the saturation solubility when the particle size is less than one micrometer, while 
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reducing the thickness of the diffusion layer [83]. Also, small substances are more likely to 
cross the intestinal barrier thereby increasing their permeability [84].
The reduction in particle size has two components, namely micronization giving less than one 
millimeter size particles and the formation of nanoparticles with less than one micrometer size 
particles. The most common micronization technique consists of mechanical dry pulverization 
of larger drug particles, mainly using jet, ball and pin mills. The lowest particle size that can be 
achieved is about 2–3 µm. Also, the agglomeration of drug particles sometimes increases, 
resulting in the decrease of the surface available for dissolution. In such a case, wetting agents 
like surfactants would play a major role in increasing the effective area [45]. Nanoparticles are 
commonly produced by controlled precipitation, crystallization, high pressure homogenization, 
wet-milling with beads and use of supercritical fluids [85]. These particles are very cohesive 
with a strong tendency for aggregation, hence the need to disperse them in hydrophilic polymers 
and/or surfactants for more stability. Drug nanoparticles have many benefits, compared to the 
simple micronized drug powders. In fact, the increase in surface area to mass ratio for 
nanoparticles is much more drastic than that of microparticles, sometimes covering several 
orders of magnitude [86]. A review of the literature on the bioavailability of poorly soluble 
substances showed that the nanoparticle formulations allow 1.7–60-fold and 2–30-fold 
enhancements in Cmax and AUC respectively, compared to those of crystalline microparticles 
[45].
3.3.1 Ellagic acid microparticles formation 
Various authors used micronization techniques to improve EA biopharmaceutical properties. 
Indeed, Li et al. (2015) used antisolvent precipitation and freeze-drying to prepare micronized 
EA (m-EA) powder for oral delivery. N-methyl pyrrolidone (NMP) and deionized water were 
utilized as solvent and antisolvent. The resulting precipitate was centrifuged and lyophilized to 
give m-EA powder. This powder was then characterized by scanning electron microscopy, 
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FTIR, liquid chromatography tandem mass spectrometry, X-ray diffraction, differential 
scanning calorimetry, thermogravimetric analysis and by in vitro dissolution and solubility 
tests. The results indicated a strong reduction in the crystallinity of m-EA compared to the raw 
EA. In addition, the apparent solubility obtained with m-EA was approximately 6.5 times higher 
than that of the EA. More interesting, bioavailability following oral administration in rats was 
about 2 times higher with m-EA (fig. 8) [87].
                                 
Fig. 8 : Bioavailability results obtained after oral administration in rats of equivalent amounts 
of 2 mg EA. (a) raw EA, (b) physical mixture of maltodextrin and raw EA, (c) pomegranate 
herbal supplement, (d) m-EA freeze-dried powder. Reprint with permission from [87].            
Montes et al. (2016), using the supercritical anti-solvent process (SAS) to generate m-EA and 
m-EA / Eudragit L100 coprecipitates, observed that the crystallinity and stability of SAS-
processed EA remained unchanged and the coprecipitates released EA more rapidly than EA 
microparticles. This faster release would be explained by the fact that smaller EA microparticles 
were obtained in the presence of the polymer [88]. Jeong et al (2001) used Eudragit P-4135F, 
a pH-sensitive polymer, to deliver EA microspheres into the lower small intestine in rats. They 
obtained an effective release of EA at the desired site. Also, dissolution tests showed a release 
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of more than 95% of EA after 30 min from the microspheres in pH 7.4 and pH 8 buffer, and 
less than 40% from EA raw powder [89]. Alfei et al. (2019) prepared by spray drying a micro-
dispersion form of EA in weakly methoxylated pectin, which was 30 times more soluble than 
pure EA [90].
3.3.2 Ellagic acid nanoparticles formation 
Nanotechnology, especially made with stabilizer polymers, seems to promote oral availability 
of EA. Bala et al. (2005, 2006) produced EA loaded in poly (D,L-lactide-co-glycolide) 
nanoparticles, using polyvinyl alcohol (PVA), didodecyldimethylammonium bromide 
(DMAB) and PVA in combination with chitosan (80:20) as stabilizer. The intestinal 
permeability test performed in situ in the rat showed 66%, 75%, 73% and 87% permeation, 
respectively for pure drug and the drug encapsulated in nanoparticles prepared using PVA, 
PVA– chitosan blend and DMAB as stabilizer [36,91]. Mady and Shaker (2017) showed that 
the in vivo bioavailability of EA obtained in the rabbits was 3.6 times higher from EA / Poly ε-
caprolactone nanoparticles produced by emulsion-diffusion-evaporation technique, compared 
to that of pure EA (Fig. 9) [92].
                                   
Fig. 9 : Plasma concentration - time curves of EA after oral administration to NZW rabbits at 
50 mg/kg equivalent dose of free EA and EA / Poly ε-caprolactone nanoparticles made by 
emulsion-diffusion-evaporation technique. Reprint with permission from [92].
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Biodegradable hollow zein nanoparticles with a mean diameter of about 70 nm for oral 
administration of EA have also been developed. The inner core, which consists of EA / sodium 
carbonate (EA / Na2CO3) obtained by coprecipitation, was then encapsulated in hollow zein 
nanoparticles (HTZN) with triethyl citrate as a plasticizer. The bioavailability in the rat was 3.6 
and 2.6 times higher than that of pure EA and non-encapsulated nanoparticles of EA [93]. Alfei 
et al. (2019) have, for their part, produced nanoparticles of hydrophilic and amphiphilic non-
polyamidoamine dendrimers of size between 60 and 70 nm and incorporating 46% and 53% (w 
/ w) of EA. The resulting products have shown a water solubility of 300 to 1000 times higher 
than that of free EA [90]. 
Considering the high degree of crystallinity of EA, particle size reduction and more specifically 
nanonization, could be one of the best approaches to improve its solubility. Indeed, EA 
nanonization may reduce this crystal lattice force, increase the surface to volume ratio and 
improve solubility and dissolution rate, as evidenced by the significant results obtained by 
scientists in terms of improvement in solubility and bioavailability. However nanoparticles 
present various drawbacks such as their high cohesivity requiring stabilization to avoid 
aggregation and complex manufacturing issues [94].
3.4 Lipid-based formulations containing ellagic acid
Lipid-based formulations or Lipid-Based Drug Delivery Systems (LBDDS) are another 
formulation strategy used to overcome the low bioavailability of poorly water-soluble drugs 
[95]. Sustivas®, Fortovases®, Nor-virs®, Lamprenes®, SandimmuneTM and NeoralTM are 
examples of marketed LBDDS. Indeed, for many of these drugs, it is recognized that 
administration with fatty foods improves bioavailability [89,90]. The presence of exogenous 
fatty foods in the small intestine stimulates the endogenous secretion of bile salt and cholesterol, 
which increases the solubilization and absorption of lipid digestion products and drugs [98]. To 
successfully develop LBDDS, several complex biological processes, such as the digestion of 
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lipid excipients, the formation of different colloidal phases during lipid digestion and the release 
of the drug from these colloidal phases must be taken into account [99].
Pouton developed a Lipid-based Formulation Classification System (LFCS) and categorized 
the lipid-based formulations into four different types (Table II) according to their compositions 
[96,97]. They range from simple oil solutions to complex mixtures of oils, surfactants, co-
surfactants and cosolvents [100]. From a biopharmaceutical point of view, any compound from 
the four BCS classes can be used in lipid-based formulations [101,102]. However, poorly water-
soluble drugs with a Log P about 2 and high melting point (above 200°C), known as brisk dust, 
are not good candidates, unlike the so-called grease balls (log P greater than 2) [99]. Similarly, 
according to some authors, only drugs having an aqueous solubility inferior to 10 µg/mL, a Log 
P superior to 5, a solubility in oils and lipids above 25 mg/mL, a relatively low melting point 
and a good chemical stability, can be good candidates for lipid formulations [103]. Savla et al., 
on the other hand, consider that types IIIB and IV lipid formulations are more suitable for brick 
dust compounds and those of types I, II and IIIA, for grease balls [104].
Table II : Characteristics and compositions of the four types of formulations, according to the 
lipid formulation classification system (LFCS) [97,104].






















Limited or no 
dispersion
Digestion required




needed to form an 
emulsion
Likely to require 
digestion
40-80 20-60 - -
III A SMEDDS
Rapid dispersion to 
form micro- or nano-
emulsion
May need digestion
40-80 - 20-40 0-40
III B SMEDDS
Rapid dispersion to 
form micro- or nano-
emulsion
Digestion likely not 
needed
<20 - 20-50 20-50
IV Oil free
Rapid dispersion 
results in micellar 
solution
No digestion needed
- 0-20 30-80 0-50
SEDDS: Self-emulsifying drug delivery system; SMEDDS: Self-microemulsifying drug 
delivery system.
Wang et al. (2017) produced a self-nanoemulsifying drug delivery system (SNEDDS) intended 
to enhance the solubility and absorption of EA and therefore, its oral bioavailability. With an 
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optimal formulation consisting of PEG, polysorbate, caprylic/capric triacylglycerol, they 
obtained a fine nanoemulsion with a mean droplet size of about 120 nm. The pharmacokinetic 
study in rats (fig.10) showed that EA was 6.6 and 3.2 times more bioavailable with this 
formulation than with aqueous suspensions and pomegranate extract, respectively [105].
 
Fig. 10 : Mean plasma concentration/time profiles of EA after oral administration to rats of EA-
SNEDS, pomegranate extract or aqueous suspension, at 17.6 µmol/kg body weight EA 
equivalent. Reprint with permission from [105].
 In order to improve EA solubility and permeability, SNEDDS formulation EA–phospholipid 
complex (EAPL complex) of 106 ± 0.198 nm vesicle size has been developed. For this purpose, 
EAPL complex prepared by the antisolvent precipitation method with soy lecithin, was then 
used to produce SNEDDS. The average vesicle size of the EAPL complex SNEDDS obtained 
was 106 ± 0.198 nm and its aqueous solubility was three times that of free EA. Ex vivo 
permeability studies performed in rats showed 84% and 94% of absorption rate in the stomach 
and small intestine and 23% and 30%, respectively for EAPL complex SNEDDS and EA 
aqueous suspension [106]. Hydrogenated soy phosphatidylcholine (HSPC) was also used to 
prepare EA - Phospholipid complex by the antisolvent precipitation method. An oral 
administration in rats of an equivalent dose of 80 mg/kg of complex and free EA, resulted in 
Cmax of 0.54 µg/mL and 0.21 µg/mL (fig.11), respectively [107].  
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Fig. 11 : Plasma EA concentration obtained after oral administration in rats of a dose of 80 
mg/kg of free EA and EA-phospholipid complex. Reprint with permission from [107].
With an optimal formulation consisting of 10% ethyl oleate, 67.5% Tween 80, 22.5% 
polyethylene glycol 400, 0.5% polyvinylpyrrolidone K30 and 4 mg g-1 EA, Zheng et al. (2019) 
developed a self-microemulsifying supersaturated drug delivery system (S-SMEDDS) to 
improve the solubility of EA. The results of the in vitro dissolution study showed that EA could 
dissolve from the S-SMEDDS within a short time and exhibited more rapid release from S-
SMEDDS than from SMEDDS and raw material [108]. 
Despite the low lipophilicity (log P =1.05) and high crystallinity (melting point ˃ 360°C) of 
EA, LBDDS, especially SNEDDS, have led to interesting improvements in the solubility and 
bioavailability of EA. This could be explained by the combined effects of particle size reduction 
and the use of formulation adjuvants. However, the complexity of LBDDS with numerous 
possible combinations of excipients, makes formulation development resource- and time-
consuming, and also requires a significant amount of API [109]. 
As described above, several strategies have been used in numerous preclinical studies to bring 
up EA, a low soluble and low permeable drug, to a bioavailable and effective therapeutic one. 
They are summarized in table III.
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Maximum EA concentration from amorphous dispersion obtained by 
dissolution test was 1500 µg/mL with PVP, 280 µg/mL with 




β-CD, HP- β-CD Formation of 1:1 stoichiometric complex, 2.2 times and 2.6 times 
increase in solubility of EA with β-CD and HP-β-CD respectively, 




HP- β-CD Formation of EA-HP-B-CD complex of 1: 2 stoichiometry;
AN-type solubility curve obtained with cyclodextrin concentrations 
ranging from 0-24mM;
An improvement of 5.5 times the dissolution rate after 15 min 






β-CD The aqueous solubility of EA drops increases from 10.37 µg / ml to 
39.14 µg / ml (3.77 times) after interaction with β-CD in a 





Methods Specific adjuvants used Main result obtained References
- methyl β-CD 7-fold increase in bioavailability after 30 min; [80]
Liquid phase 
method
β-CD, cross-linked by 
dimethyl carbonate 
(DMC)









The water solubility of free EA and m-EA at 37±0.5 C was 1.80 ± 0.9 
µg/mL and 11.67 ± 0.46 g/mL, respectively;






Supercritical CO2, NMP, 
Eudragit L 100
Faster release of coprecipitates EA/Eudragit L100 than the EA 




Spray drying Water, low methoxylated 
pectin
EA solid microdispersion aqueous solubility was 300 µg/mL and that 





Methods Specific adjuvants used Main result obtained References
Co-precipitation Ethanol, deionized water, 
zein, Na2CO3
Cmax of EA-HTZN was 0.34 μg·L−1 versus 0.085 μg·L−1 for pure 





Poly ε-caprolactone, PEG 
200, ethyl acetate, water






Two EA nanodispersions were achieved (60–70 nm) with 46% and 
53% (w/w) DL;






glycolide), PEG 400, 
DMAB, PVA, chitosan
The permeation of free EA through the jejunum was 66% and that of 
the drug encapsulated in poly (D,L-lactide-co-glycolide) 
nanoparticles using PVA, VA-chitosan mixture and DMAB as 








Span 80 and Tween 80





Mixing using a 
vortex mixer




Increase of the EA bioavailability by 6.6 and 3.2 times, compared to 













soy lecithin/EA complex 
(3%), captex (40%), 
cremophor RH 40 (40%), 
PEG 400 (20%) and 
tocopherol (0.15%)
Tripling of EA aqueous solubility;
Increase of the ex vivo absorption rate of EA in the rat stomach and 
small intestine, from 23 and 30% for EA aqueous suspension to 84% 






2.5-fold increase of the bioavailability;
Better protection of the liver by the complex and maintains an 
effective concentration for a longer period in the serum.
[107]
Mixing using a 
vortex mixer
Ethyl oleate10%, Tween 




Particles were spherical with a size of about 40 nm; dissolution of EA 
from the S-SMEDDS within a short time and exhibited more rapid 




The low absorption of EA could be attributed mainly to its very low solubility (less than 
10µg/mL) but also to its low lipophilicity (log P=1.05) and its degradation at the intestinal level 
by the bacterial flora. Also, as a weak acid ionized at more than 50% in the intestine with a pH 
of 6.8, its absorption is limited since only the un-ionized fraction is available to cross the cell 
membrane because of the lipid nature of the membrane. Its low solubility could be explained 
by its high degree of crystallinity. Indeed, with its estimated melting temperature of more than 
360°C, EA belongs to the group of molecules called "brick dust" which are soluble neither in 
water nor in oils. According to the decision tree for preclinical formulations of APIs with 
solubility limiting bioavailability (fig. 12), the use of co-solvents, nanoparticles or SD are the 
recommended formulation approaches for drugs with low log P and high melting point like EA 
[110]. 
Fig. 12 : Decision tree for preclinical formulation based on the assessment of melting point and 
Log P. Adapted with permission from [110].
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Being high cohesive crystal and weak acid, one of the best approaches to improve solubility, 
absorption in stomach and bioavailability of EA would consist in trapping its amorphous 
metastable form in acid-soluble polymers (amorphization by SD formation). A successful 
example of this type of formulation has indeed allowed to multiply the solubility and the 
bioavailability of atorvastatin by 74 and more than three, respectively. In this study, ASD of 
atorvastatin, a weak acid drug in BCS class II, and Eudragit® EPO, an acrylic derivative soluble 
in water at pH less than 5, were formed by co-precipitation [111]. Similar results have been 
obtained with ASD of curcumin, a polyphenolic compound in BCS class IV, and Eudragit® 
EPO [112]. The authors explain these good results by the existence of cation / anion interactions 
between Eudragit® EPO and the weak acids used. As such interactions can also occur, the ASD 
of EA and Eudragit® EPO could be successfully developed. Based on the empirical guide for 
selecting solid dispersion technology (fig.13) and with regard to the physicochemical properties 
of EA, only the KinetiSol® method, a recent melt-based processing technique capable of 
imparting high shear rates to the materials, appears to be more suitable for producing these 
ASD. This technique has already allowed the formation of ASD of meloxicam, another high 
melting point API (270°C) [113].
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Fig.13 : Empirical guide to select a solid dispersion technology based on physicochemical 
properties of the API. Reprint with permission from [114].
Another approach that may be appropriate to improve the solubility of brick dust compounds 
such as EA is the formation of nanoparticles. Indeed, a crystalline material is depicted as having 
three-dimensional long-range symmetry operators over a domain of at least 1000 individual 
molecules. As a consequence, a dramatic reduction in crystal size leads to a decrease in 
crystallinity and melting temperature, that can increase the solubility [115]. This probably 
explains the fact that most drastic increases in EA solubility reported in the literature have been 
observed with the nanonization approach. The same way, some authors have increased the 
solubility and dissolution rate of griseofulvin, another high-melting point compound [116,117]. 
Beyond the traditional methods of particle size reduction mentioned above (3.3), hot melt 
extrusion can also increase the solubility of high-melting compounds, by considerably reducing 
their particle size and dispersing them on amorphous polymers [118].
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Finally, being soluble in a solvent of pharmaceutical interest such as PEG 400, solution 
formulations for oral administration can be considered with EA.  
5. Conclusion
Despite its many interesting therapeutic activities demonstrated in preclinical studies, EA fails 
to dissolve adequately in gastrointestinal fluids, to pass through the gastrointestinal membrane 
to the circulatory system and to reach the target in sufficient quantities after oral administration. 
Indeed, limited solubility of API may result in insufficient and variable absorption, which lead 
to unacceptable bioavailability and inadequate clinical efficacy. In order to overcome the 
biopharmaceutical challenge of EA, many physical formulation approaches to improve its 
solubility and therefore its bioavailability, have been employed by scientists. Among these 
approaches, cyclodextrin complexation, nanoparticle formation and lipid-based formulation of 
EA, have been widely studied. However, based on its physicochemical properties (high melting 
point, low log P), the use of co-solvents, nanoparticles or SD seem to be the most appropriate 
formulation approaches for EA. The use of amorphization, through the formation of SD, has 
received very little consideration in spite its high potential for improving EA solubility and the 
current success of ASD in improving solubility and dissolution rate of BCS II and BCS IV 
molecules. The reason could be its very high melting point and low solubility in organic 
solvents, making the use of conventional techniques to produce EA - ASD difficult. The recent 
KinetiSol® technology, a high-energy, solvent-free, thermokinetic method for manufacturing 
ASD, could provide a solution to this problem. It could thus allow the preparation of amorphous 
form of EA which can drastically increase its real solubility. However, the results obtained from 
some EA formulations, which allowed a solubility increase up to 1000 times, suggest that the 
development of effective oral formulations for EA can be speed-up.
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